Hyundai Pharm Cash Flow-to-Debt Ratio
Hyundai Pharm cash flow-to-debt ratio. Hyundai Pharm (004310) has a Cash Flow-to-Debt Ratio of 0.02x as of May 2026, meaning its operating cash flow of ₩2.39 Billion could theoretically repay 0% of its total liabilities (₩96.64 Billion) in one year. Check 004310 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hyundai Pharm (2010–2025)
Cash flow-to-debt ratio of Hyundai Pharm from 2010 to 2025. Historical debt coverage capacity for Hyundai Pharm across 14 annual periods. Check 004310 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Hyundai Pharm Cash Flow-to-Debt Ratio by Year (2010–2025)
Hyundai Pharm cash flow-to-debt ratio by year from 2010 to 2025. Year-by-year debt coverage analysis for Hyundai Pharm. For the full cash flow conversion analysis, see 004310 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | ₩-123.29 Million | ₩81.11 Billion | ▲ +95.0% |
| 2024 | -0.03x | ₩-2.37 Billion | ₩77.32 Billion | ▲ +52.8% |
| 2023 | -0.06x | ₩-4.55 Billion | ₩69.97 Billion | ▼ -152.9% |
| 2022 | 0.12x | ₩11.62 Billion | ₩94.60 Billion | ▲ +85.0% |
| 2021 | 0.07x | ₩5.13 Billion | ₩77.26 Billion | ▼ -58.6% |
| 2020 | 0.16x | ₩10.80 Billion | ₩67.36 Billion | ▲ +33.4% |
| 2019 | 0.12x | ₩6.96 Billion | ₩57.89 Billion | ▲ +119.8% |
| 2018 | 0.05x | ₩2.83 Billion | ₩51.80 Billion | ▲ +256.1% |
| 2017 | -0.04x | ₩-1.98 Billion | ₩56.52 Billion | ▲ +35.6% |
| 2016 | -0.05x | ₩-2.75 Billion | ₩50.47 Billion | ▼ -128.9% |
| 2013 | 0.19x | ₩7.95 Billion | ₩42.19 Billion | ▲ +450.9% |
| 2012 | -0.05x | ₩-2.70 Billion | ₩50.22 Billion | ▼ -145.1% |
| 2011 | 0.12x | ₩6.27 Billion | ₩52.63 Billion | ▲ +71.1% |
| 2010 | 0.07x | ₩2.68 Billion | ₩38.48 Billion | — |